Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Subscribe To Our Newsletter & Stay Updated
